HC Wainwright Has Positive Opinion of AUTL FY2027 Earnings

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Free Report) – Equities researchers at HC Wainwright raised their FY2027 earnings estimates for Autolus Therapeutics in a research note issued on Wednesday, November 11th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of ($0.69) for the year, up from their prior forecast of ($0.74). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ FY2028 earnings at ($0.81) EPS, FY2029 earnings at ($0.69) EPS and FY2030 earnings at ($0.22) EPS.

AUTL has been the topic of a number of other reports. UBS Group reiterated a “buy” rating on shares of Autolus Therapeutics in a report on Wednesday. Weiss Ratings cut shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, November 3rd. Finally, Wall Street Zen upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Autolus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Get Our Latest Research Report on AUTL

Autolus Therapeutics Stock Down 1.7%

Autolus Therapeutics stock traded down $0.02 during midday trading on Friday, reaching $1.17. The stock had a trading volume of 1,788,996 shares, compared to its average volume of 2,658,964. The stock has a market capitalization of $311.62 million, a P/E ratio of -1.21 and a beta of 2.32. The firm’s fifty day simple moving average is $1.70 and its 200-day simple moving average is $1.66. The company has a debt-to-equity ratio of 5.25, a quick ratio of 4.40 and a current ratio of 3.72. Autolus Therapeutics has a 1-year low of $1.12 and a 1-year high of $2.58.

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). The company had revenue of $41.24 million during the quarter, compared to analysts’ expectations of $39.54 million. Autolus Therapeutics had a negative return on equity of 263.25% and a negative net margin of 186.37%. During the same period in the prior year, the firm earned ($0.30) earnings per share.

Hedge Funds Weigh In On Autolus Therapeutics

Large investors have recently modified their holdings of the stock. Syncona Portfolio Ltd bought a new position in Autolus Therapeutics during the 2nd quarter worth $26,625,152. Alphabet Inc. acquired a new stake in shares of Autolus Therapeutics during the second quarter worth $1,117,000. Private Advisor Group LLC bought a new stake in shares of Autolus Therapeutics in the third quarter valued at about $28,000. Privium Fund Management B.V. boosted its position in shares of Autolus Therapeutics by 29.2% in the third quarter. Privium Fund Management B.V. now owns 469,490 shares of the company’s stock valued at $911,000 after acquiring an additional 106,060 shares during the period. Finally, Vise Technologies Inc. bought a new stake in shares of Autolus Therapeutics in the third quarter valued at about $35,000. 72.83% of the stock is owned by institutional investors.

About Autolus Therapeutics

(Get Free Report)

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing engineered T-cell therapies for cancer. Its treatments are designed to program a patient’s T cells to recognize and attack specific cancer cells, using the company’s proprietary cell-engineering technology. The company’s lead therapy, obecabtagene autoleucel (obe-cel), is marketed as Aucel and is approved in the United States and European Union for certain adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Read More

Earnings History and Estimates for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.